ANI Pharmaceuticals
ANIP
184 hedge funds and large institutions have $480M invested in ANI Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 71 increasing their positions, 43 reducing their positions, and 19 closing their positions.
149% more call options, than puts
Call options by funds: $8.13M | Put options by funds: $3.26M
65% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 43
47% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 19
25% more capital invested
Capital invested by funds: $386M → $480M (+$94.8M)
5% more funds holding
Funds holding: 175 → 184 (+9)
4.15% more ownership
Funds ownership: 56.85% → 60.99% (+4.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.92M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$4.93M |
| 3 |
Boston Partners
Boston,
Massachusetts
|
+$2.94M |
| 4 |
PFC
Phocas Financial Corp
Alameda,
California
|
+$2.61M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$2.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.77M |
| 2 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$2.49M |
| 3 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$2.43M |
| 4 |
JG
Jefferies Group
New York
|
-$1.7M |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$1.14M |
ANIP Hedge Fund Activity: Q2 2018 in Review
184 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q2 2018, worth a combined $480M — up 25% from $386M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new ANIP positions and 19 closed out — a net gain of 9 holders — while 71 added to existing stakes and 43 trimmed.
The largest buyer was BlackRock, adding an estimated $5.92M. The largest seller was Millennium Management, exiting entirely with an estimated $2.77M sold.
- 184 institutional investors held ANI Pharmaceuticals (ANIP) as of Q2 2018, up from 175 in Q1 2018.
- Funds reported $480M of ANI Pharmaceuticals stock for Q2 2018, up 25% quarter-over-quarter.
- 28 funds opened new ANI Pharmaceuticals positions in Q2 2018 and 19 closed out, a net change of +9 holders.
- The largest ANI Pharmaceuticals buyer in Q2 2018 was BlackRock, an estimated $5.92M added.
- The largest ANI Pharmaceuticals seller in Q2 2018 was Millennium Management, an estimated $2.77M sold.
Based on aggregated 13F filings for Q2 2018.